The Ledger

MRNA

Moderna IncHealth Careinsider_universe

Last close $69.49Jun 28, 2026

Day +3.30%

Currently held

Agent 20 — SIR Price/Volumelong
31 sh @ $55.38 · stop $48.73
+$423.46 unrealized

Everything we've seen

·Jun 29, 3:48 PMstreamnews
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
·Jun 29, 3:48 PMstreamnews
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
·Jun 29, 3:48 PMstreamnews
This COVID Stock Market Winner Is Making a Comeback, Up 125% Year to Date
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
·Jun 29, 3:48 PMstreamnews
US Stock Market Today: S&P 500 Futures Slip As Sticky Inflation Keeps Fed Cautious
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
·Jun 29, 3:33 PMstreamnews
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
·Jun 29, 3:33 PMstreamnews
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
·Jun 29, 3:33 PMstreamnews
This COVID Stock Market Winner Is Making a Comeback, Up 125% Year to Date
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
·Jun 29, 3:33 PMstreamnews
US Stock Market Today: S&P 500 Futures Slip As Sticky Inflation Keeps Fed Cautious
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
·Jun 29, 3:18 PMstreamnews
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
·Jun 29, 3:18 PMstreamnews
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
·Jun 29, 3:18 PMstreamnews
This COVID Stock Market Winner Is Making a Comeback, Up 125% Year to Date
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
·Jun 29, 3:18 PMstreamnews
US Stock Market Today: S&P 500 Futures Slip As Sticky Inflation Keeps Fed Cautious
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
·Jun 29, 3:04 PMstreamnews
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
·Jun 29, 3:04 PMstreamnews
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
·Jun 29, 3:04 PMstreamnews
This COVID Stock Market Winner Is Making a Comeback, Up 125% Year to Date
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
·Jun 29, 3:04 PMstreamnews
US Stock Market Today: S&P 500 Futures Slip As Sticky Inflation Keeps Fed Cautious
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
·Jun 29, 2:48 PMstreamnews
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
·Jun 29, 2:48 PMstreamnews
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
·Jun 29, 2:48 PMstreamnews
This COVID Stock Market Winner Is Making a Comeback, Up 125% Year to Date
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
·Jun 29, 2:48 PMstreamnews
US Stock Market Today: S&P 500 Futures Slip As Sticky Inflation Keeps Fed Cautious
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
·Jun 29, 2:33 PMstreamnews
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
·Jun 29, 2:33 PMstreamnews
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
·Jun 29, 2:33 PMstreamnews
This COVID Stock Market Winner Is Making a Comeback, Up 125% Year to Date
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
·Jun 29, 2:33 PMstreamnews
US Stock Market Today: S&P 500 Futures Slip As Sticky Inflation Keeps Fed Cautious
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
!Jun 29, 9:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 29, 7:06 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 29, 5:45 AMnewsvia finnhub
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side
The week closed with the Strait of Hormuz still bleeding headlines and crude already down nine percent. Sunday, Washington and Tehran said they were standing down and heading to Doha. Whether that holds is anyone's guess, but for one trading day, at least, the market gets to price the calmer outcome.
❖Jun 29, 4:08 AMnewsvia finnhub
US Stock Market Today: S&P 500 Futures Slip As Sticky Inflation Keeps Fed Cautious
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
❖Jun 29, 3:25 AMnewsvia finnhub
This COVID Stock Market Winner Is Making a Comeback, Up 125% Year to Date
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
❖Jun 29, 1:55 AMnewsvia finnhub
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
❖Jun 28, 11:56 PMnewsvia finnhub
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
❖Jun 26, 6:05 PMnewsvia finnhub
S&P 500 ends lower; chips tumble and Moderna rallies
STORY: U.S. stocks ended marginally lower on Friday, with the Dow and S&P 500 each shedding less than a tenth of a percent, and the Nasdaq losing about a quarter of a percent.AI-related chip stocks suffered steep declines as some investors worry that the massive spending to build AI data centers may take too long to pay off.Robert Conzo is CEO and managing director of The Wealth Alliance."The AI ship, although we love the technology, everyone loves the idea, it's like a cruise ship where the captain knows where they're going, the passengers don't know where this is going, passengers get nervous. The captain is the CEOs of these companies, putting billions and billions and billions of dollars of infrastructure into the AI. The market is the passengers saying, 'When are we going to be profitable here? At what point does profitability come to play?' Analysts are saying 2030, could be longer. And when prices go up, up, up, up higher, suddenly you start to question that value."A report that OpenAI was considering delaying its public debut until next year also weighed on risk sentiment related to AI stocks.:: AppleElsewhere in the market, shares of Apple rallied more than 3% and partly rebounded from a selloff a day earlier. The tech giant on Thursday raised iPad and MacBook prices, blaming soaring memory and storage chip costs.:: ArchiveShares of ON Semiconductor tumbled almost 24% after the company agreed to acquire chip maker Synaptics in an all-stock deal valued at about $7 billion. Shares of Synaptics dipped more than 3.5%.:: ModernaOn the flipside, shares of Moderna surged almost 13% to their highest level since 2024 after the drug developer hosted an investor event and showcased its pipeline.
❖Jun 26, 4:19 PMnewsvia finnhub
US Equity Markets End Lower Amid Technology Stocks Sell-Off
US equity indexes were lower on Friday amid a sell-off in technology stocks and despite a decline in
❖Jun 26, 4:11 PMnewsvia finnhub
Stocks Struggle After OpenAI IPO Blow: Stock Market Today
Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.
❖Jun 26, 3:54 PMnewsvia finnhub
Trending: Netflix stock bounces back, Moderna surges post–investor day, ON Semi plummets
Yahoo Finance's Jared Blikre takes a closer look at some of Friday's trending tickers and stories, including Moderna (MRNA), Netflix (NFLX), and ON Semiconductor (ON).
❖Jun 26, 3:05 PMnewsvia finnhub
Discover which S&P500 stocks are making waves on Friday.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
❖Jun 26, 1:49 PMnewsvia finnhub
Lilly, J&J and AbbVie Hit New Highs
Lilly, AbbVie and J&J extend winning streaks.
❖Jun 26, 1:06 PMnewsvia finnhub
CNBC Markets Now: June 26, 2026
CNBC Markets Now provides a look at the day's market moves with commentary and analysis from Michael Santoli, CNBC Senior Markets Commentator.
❖Jun 26, 1:05 PMnewsvia finnhub
Post Market Wrap: June 26, 2026
CNBC brings you fast, accurate, and actionable business news and market updates.
❖Jun 26, 12:35 PMnewsvia finnhub
Friday's session: top gainers and losers in the S&P500 index
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.
❖Jun 26, 12:24 PMnewsvia finnhub
3 Mid-Cap Stocks Walking a Fine Line
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
❖Jun 26, 12:22 PMnewsvia finnhub
Moderna, Nvidia, Sandisk, Palantir, ON Semi, and More Stocks That Explain Today’s Market
Investors continued to rotate out of artificial-intelligence momentum names and into lagging sectors. Flash memory product supplier Sandisk fell 7.8% and is set to close lower on the week after rising 22% on Thursday. Nvidia moved 0.8% lower to $194.12.
❖Jun 26, 12:01 PMnewsvia finnhub
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
!Jun 26, 11:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 11:36 AMnewsvia finnhub
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
!Jun 26, 10:48 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 10:06 AMnewsvia finnhub
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its Duchenne muscular dystrophy therapy.
❖Jun 26, 9:10 AMnewsvia finnhub
CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low
https://www.cdc.gov/ebola/situation-summary/index.html
❖Jun 26, 8:59 AMnewsvia finnhub
Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more
Here are the companies making headlines in midday trading.
❖Jun 26, 8:48 AMnewsvia finnhub
Piper Sandler Maintains Overweight on Moderna, Raises Price Target to $77
Piper Sandler analyst Edward Tenthoff maintains Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $69 to $77.
❖Jun 26, 8:22 AMnewsvia finnhub
Chip Rout Drags Nasdaq 100, Oil Sinks Below $69: Stock Market Today
Semiconductors cratered Friday, dragging the stock market lower, while health care and software led a rotation and oil sank below $69
❖Jun 26, 7:36 AMnewsvia finnhub
The Late Morning Rundown: June 26, 2026
CNBC brings you fast, accurate, and actionable business news and market updates.
?Jun 26, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
!Jun 26, 7:04 AMsignalseverity 0.12
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
?Jun 26, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
!Jun 26, 7:03 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
❖Jun 26, 6:18 AMnewsvia finnhub
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc (NASDAQ: FCEL) up 17.6%, BitVentures Limited (NASDAQ: BVC) up 14.1%, and ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) up 10.3% after receiving a positive recommendation for a market authorization in Europe.
❖Jun 26, 1:20 AMnewsvia finnhub
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst
It's not just a "pandemic stock," after all.
❖Jun 25, 11:12 PMnewsvia finnhub
Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science
2026-06-26. The following slide deck was published by Moderna, Inc.
❖Jun 25, 11:08 PMnewsvia finnhub
MRNY: The Yield Is Too Aggressive For Long-Term Sustainability
❖Jun 25, 5:32 PMnewsvia finnhub
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science June 25, 2026 9:00 AM EDTCompany...
!Jun 25, 9:21 AMsignal
Agent 6 — Options Momentum — insufficient_capital
?Jun 25, 7:05 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
!Jun 25, 7:05 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
?Jun 25, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
!Jun 25, 7:03 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
!Jun 25, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 7:00 AMnewsvia finnhub
Moderna Science Day Highlights Expanding Potential of mRNA Platform
Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell ...
❖Jun 25, 3:12 AMnewsvia finnhub
Moderna Outlines Research And Early Development Programs Fueling Future Growth; Highlights T‑Cell Engager Modality And Unveils In Vivo CAR‑T Entry
Provides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting
❖Jun 24, 7:15 PMnewsvia finnhub
How Unanimous FDA Panel Support For mRNA Flu Shot At Moderna (MRNA) Has Changed Its Investment Story
The FDA’s Vaccines and Related Biological Products Advisory Committee has unanimously backed Moderna’s mRNA-based flu shot, mFlusiva, for adults 50 and older, after phase 3 data showed it to be about 27% more effective than a standard flu vaccine. This endorsement positions Moderna’s mRNA platform for a potential second major commercial use beyond COVID-19, expanding its role in routine respiratory vaccination for older adults. We’ll now explore how this unanimous FDA panel support for...
?Jun 24, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
!Jun 24, 6:06 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
?Jun 24, 6:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA is down 12.4% from its 30-day high, with today's drop ending a 6-day rally and placing it among the S&P 500's biggest losers — suggesting mean-reversion exhaustion rather than a fundamental catalyst. No SEC filings were available to assess current financial health, but there are no visible signs of guidance cuts, accounting issues, or fraud in the evidence. However, Moderna remains a structurally challenged company with a declining mRNA vaccine revenue base, high cash burn, and a thin near-term pipeline catalyst calendar, making a swift rebound to the 30-day high within 90 days uncertain.
!Jun 24, 6:06 PMsignalseverity 0.11
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MRNA is down 12.4% from its 30-day high, with today's drop ending a 6-day rally and placing it among the S&P 500's biggest losers — suggesting mean-reversion exhaustion rather than a fundamental catalyst. No SEC filings were available to assess current financial health, but there are no visible signs of guidance cuts, accounting issues, or fraud in the evidence. However, Moderna remains a structurally challenged company with a declining mRNA vaccine revenue base, high cash burn, and a thin near-term pipeline catalyst calendar, making a swift rebound to the 30-day high within 90 days uncertain.
?Jun 24, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
!Jun 24, 6:06 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
!Jun 24, 6:05 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 5:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 5:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 5:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 4:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 4:33 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 3:36 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 2:49 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 12:50 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 11:50 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 9:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 9:17 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 24, 12:28 AMnewsvia finnhub
Moderna: Flu Vaccine Progress Is Only Part Of The Story
Moderna received a unanimous advisory committee vote supporting mRNA-1010, its flu vaccine, for adults 50 and older. Read more on MRNA stock here.
❖Jun 23, 6:45 PMnewsvia finnhub
Flagship Pioneering and Lean Business Services Company Announce Collaboration to Advance Healthcare Innovation and AI-Enabled Biomedical Research in Saudi Arabia
Flagship Pioneering, the scientific innovation company behind Moderna, Generate Biomedicines, and more than 100 other life sciences ventures, and Lean Business Services Company, a Public Investment Fund company and the Kingdom's national leader in digital health transformation, today announced a strategic collaboration to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia.
❖Jun 23, 5:50 PMnewsvia finnhub
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts
Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.
!Jun 23, 5:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 5:32 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 5:20 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 23, 4:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 23, 3:05 PMnewsvia finnhub
Which S&P500 stocks are moving on Tuesday?
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
❖Jun 23, 12:35 PMnewsvia finnhub
Explore the top gainers and losers within the S&P500 index in today's session.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.
?Jun 23, 10:35 AMdecisionconsidered
Agent 7 — Day Trader — analyze: fail
Claude analysis failed: Anthropic 529: {"type":"error","error":{"type":"overloaded_error","message":"Overloaded"},"request_id":"req_011CcLMkQ8c8J2Fzz17VfTzH"}
?Jun 23, 8:51 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
?Jun 23, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
?Jun 23, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
❖Jun 23, 6:25 AMnewsvia finnhub
Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade)
Moderna, Inc. analysis: VWAP resistance, R&D wins, Q1 revenue surge, and mRNA-1010 risks missed flu contractsâthe rating shifts to Sell. Click for an update.
❖Jun 23, 4:21 AMnewsvia finnhub
Moderna: The Comeback Is Now In Full Swing
Moderna, Inc. shifts beyond Covid with mRNA vaccines like mFlusiva, combo shots, and oncology catalysts. Click for more on MRNA stock prospects.
?Jun 22, 7:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MRNA is down 12.4% from its 30-day high, but the drop is idiosyncratic — the broader Health Care sector is not in freefall, and today's price action shows MRNA as one of the S&P 500's biggest losers while the market is roughly flat. Signal scoring is weak: no insider buying, no options flow data, no SEC filings to confirm fundamental health, the drop is below the 15% mean-reversion threshold (+0), no earnings in the visible window (+1), but the sector is outperforming relative to this single stock (-1), 10Y yield at 4.46% is a mild headwind for growth-sensitive biotech (-1), and the news headline confirms the stock broke a 6-day rally on fresh selling pressure (-1). Net signal score is approximately -2, which does not support a buy. Moderna's fundamental picture (heavy reliance on mRNA pipeline, declining COVID revenues, ongoing cash burn) adds structural uncertainty without recent filings to contradict it.
?Jun 22, 7:21 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA is down 12.4% from its 30-day high, with today's drop ending a 6-day rally and placing it among the S&P 500's biggest losers — suggesting mean-reversion exhaustion rather than a fundamental catalyst. No SEC filings were available to assess current financial health, but there are no visible signs of guidance cuts, accounting issues, or fraud in the evidence. However, Moderna remains a structurally challenged company with a declining mRNA vaccine revenue base, high cash burn, and a thin near-term pipeline catalyst calendar, making a swift rebound to the 30-day high within 90 days uncertain.
❖Jun 22, 6:30 PMnewsvia finnhub
Should You Buy Moderna Before Aug. 5?
Moderna just received fantastic news.
?Jun 22, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 12.4% from its 30-day high on a day when it's one of the S&P 500's biggest losers, ending a 6-day rally — suggesting the drop is a technical pullback after a short-term run rather than a new fundamental impairment. Importantly, a positive catalyst exists: Moderna's mRNA flu vaccine passed FDA AdCom with review underway, which is a meaningful pipeline milestone that supports the bull case. The macro environment is relatively benign (VIX at 46th percentile, 2s10s not inverted) and no imminent earnings binary risk is present. However, there is no insider buying, no options flow confirmation, and no SEC filings to assess balance sheet health, and today's sector context shows Health Care underperforming SPY meaningfully over 5 days (-2.79pts), suggesting sector-level headwinds rather than pure idiosyncratic recovery potential.
❖Jun 22, 3:05 PMnewsvia finnhub
Monday's session: top gainers and losers in the S&P500 index
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.
❖Jun 22, 1:46 PMnewsvia finnhub
Moderna Stock’s 6-Day Rally Ends in a Dive. Why It’s One of the S&P 500’s Biggest Losers Today.
Shares of the vaccine maker have been on a hot streak, most recently catalyzed by a positive update from the FDA.
❖Jun 22, 12:35 PMnewsvia finnhub
Explore the top gainers and losers within the S&P500 index in today's session.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.
❖Jun 22, 10:35 AMnewsvia finnhub
Which S&P500 stocks are gapping on Monday?
Looking for the S&P500 stocks that are experiencing notable gaps on Monday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
❖Jun 22, 7:43 AMnewsvia finnhub
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway
The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age groups.
▣Jun 21, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 70 @ $10.29 (+$440.79)
Stop: premium $10.29 ≤ trailing floor $10.86 (peak $14.49 × 0.75)
▣Jun 21, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 29 @ $59.35 (+$303.10)
Trailing stop on remainder: close $59.34 ≤ floor $59.48 (peak $63.96 × 0.93; floor at entry $48.89)
❖Jun 20, 7:50 AMnewsvia finnhub
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?
The company's pending vaccine approvals could help the stock continue its rise.
❖Jun 19, 8:04 AMnewsvia finnhub
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
❖Jun 19, 4:06 AMnewsvia finnhub
Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0
Moderna’s experimental flu vaccine won unanimous FDA panel backing ahead of an Aug. 5 decision.
❖Jun 18, 5:45 PMnewsvia finnhub
MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine
Jefferies noted that FDA decisions aligned with advisory committee recommendations 84% of the time between 2020 and 2025.
❖Jun 18, 4:00 PMnewsvia finnhub
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological ...
▣Jun 16, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 28 @ $61.77 (+$360.63)
Staged exit (1/2.0): close $61.77 ≥ target $59.48. Selling 28/57 sh, trailing remainder.
✓Jun 16, 6:06 PMdecisionacted
Agent 20 — SIR Price/Volume — buy
[cluster_break_up] The 20-day PV path shows MRNA oscillating in a well-defined price cluster between roughly $45.64 (2026-06-02) and $49.91 (2026-06-12) on routine volume averaging 5.3M ADV, with no single session materially exceeding that band on strong volume. The path began breaking above the cluster on 2026-06-15 ($52.13, 6.3M) and today, 2026-06-16, confirmed the breakout decisively: close $55.38 on 11.4M shares — a volume z-score of 6.11 against the trailing 20-day mean, more than doubling normal ADV and clearing the entire prior cluster range. Critically, this is not a single-bar event — the path has shown up-day volume dominance across the last five consecutive UP sessions (2026-06-11 through 2026-06-16), with volume expanding sequentially on each advance leg, satisfying the SIR requirement of a path-based, not a single-dot, signal. Risks: A failure to hold above the breakout level (~$49–$51, the top of the prior cluster) on any near-term pullback would invalidate the cluster_break_up read and suggest the 2026-06-16 volume spike was an exhaustion/climax event rather than absorption of the float. Additionally, the macro environment — with T10Y2Y at 0.4 (2.1σ below trend) signaling a flattening/mild inversion — could suppress risk appetite in speculative Health Care names and cut the follow-through window short.
✓Jun 16, 10:05 AMdecisionacted
Agent 7 — Day Trader — decide: buy
MRNA is up 2.67% today, a meaningful intraday move suggesting real buying conviction. The catalyst — organizational changes to prepare for multiple product launches in 2027-2028 — is modestly constructive, signaling management confidence in the pipeline, though it's not a blockbuster catalyst (no FDA approval, no partnership deal). With 340 minutes remaining (essentially the full afternoon session), there is ample time for continuation. The macro backdrop (T10Y2Y at 2.1σ below trend, a flattening/slightly inverted curve) is more relevant to financials and defensives than to biotech/healthcare, so macro headwinds are minimal here. No reversal signals are evident — the move appears steady rather than a spike-and-fade. The absence of a stronger headline limits conviction to the moderate range. Overall, momentum favors continuation but without a high-conviction catalyst, probability sits in the ordinary momentum band.
✓Jun 16, 9:01 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — pyramid
Pyramid add-on fired at +10.30% unrealized. Added 19 sh @ $52.14 ($990.66). Position now 57 sh @ weighted avg $48.89.
?Jun 16, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 12.3% from its 30-day high with virtually no supporting evidence to anchor a bullish thesis: no insider buying, no options flow data, no SEC filings, and the sole news headline carries a mildly negative sentiment (-0.25) referencing stocks under $50 that "fall short." The Health Care sector (XLV) is showing mild relative strength over 30 days (+0.58 vs SPY), suggesting this is an idiosyncratic move rather than a sector-wide selloff — which raises the concern of company-specific weakness. Broader market tone today is risk-on (SPY +1.76%, QQQ +3.14%), yet MRNA continues to underperform, which is a further red flag for a dip recovery in the near term.
▣Jun 15, 8:00 PMjournaltarget
Agent 6 — Options Momentum closed long 30 @ $8.18 (+$125.69)
De-risk: premium $8.18 ≥ 2.0× entry $3.99. Selling 30/100 contracts; trailing the remainder.
▢Jun 15, 8:00 PMjournal
Agent 7 — Day Trader opened long 55 @ $53.52
▣Jun 15, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 55 @ $55.33 (+$99.55)
Long target: close $55.33 ≥ target $55.13
?Jun 15, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 12.3% from its 30-day high with virtually no supporting evidence to anchor a bullish thesis: no insider buying, no options flow data, no SEC filings, and the sole news headline carries a mildly negative sentiment (-0.25) referencing stocks under $50 that "fall short." The Health Care sector (XLV) is showing mild relative strength over 30 days (+0.58 vs SPY), suggesting this is an idiosyncratic move rather than a sector-wide selloff — which raises the concern of company-specific weakness. Broader market tone today is risk-on (SPY +1.76%, QQQ +3.14%), yet MRNA continues to underperform, which is a further red flag for a dip recovery in the near term.
?Jun 15, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA is trading at $52.14, down 12.3% from its 30-day high, with minimal supporting evidence for a near-term rebound. The only news headline in the last 30 days is negative (sentiment=-0.25) and groups MRNA among stocks "falling short," suggesting weak fundamental momentum. There are no recent SEC filings to confirm financial stability, and the macro environment (a flat-to-modestly-steep yield curve at 0.39, 2.2σ below trend) is not particularly supportive for high-beta biotech names like Moderna, which has been burning cash post-COVID with no blockbuster successor yet approved.
?Jun 15, 3:41 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 5 minutes remaining until the forced close cutoff, there is virtually no time for the trade to develop further. Even a strong momentum setup cannot reasonably be expected to add meaningful continuation in 5 minutes, and the risk/reward of entering here is poor — the position would be flattened almost immediately. The 3.64% move is notable and suggests real buying pressure, but the sole headline is mildly negative ('Falls Short' framing) and the macro context (flattening yield curve favoring defensives over growth/biotech) is not supportive for MRNA. With near-zero time horizon, the probability of capturing the +3% target before forced flatten is essentially nil, and the move has likely already run its course into the close.
?Jun 15, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 16.5% from its 30-day high with zero confirmatory signals — no insider buying, no options flow, no SEC filings, and no news headlines to diagnose the cause of the drop. The stock is dipping while the Health Care sector is a strong outperformer (rank 2 of 11, +4.20pts vs SPY over 30 days), which flags idiosyncratic weakness rather than sector-wide pressure — a meaningful concern. Today's broad-market risk-on tone (QQQ +3.30%, SPY +1.70%) provides some potential tailwind, but MRNA's core fundamentals remain challenged: the company has been in post-COVID revenue decline, burning cash on next-generation mRNA pipeline investments, and trades at compressed multiples with no near-term commercial catalyst visible in the evidence. The absence of any data makes fundamental assessment speculative, but the idiosyncratic sector divergence tips the balance toward caution.
?Jun 12, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 16.5% from its 30-day high with zero confirmatory signals — no insider buying, no options flow, no SEC filings, and no news headlines to diagnose the cause of the drop. The stock is dipping while the Health Care sector is a strong outperformer (rank 2 of 11, +4.20pts vs SPY over 30 days), which flags idiosyncratic weakness rather than sector-wide pressure — a meaningful concern. Today's broad-market risk-on tone (QQQ +3.30%, SPY +1.70%) provides some potential tailwind, but MRNA's core fundamentals remain challenged: the company has been in post-COVID revenue decline, burning cash on next-generation mRNA pipeline investments, and trades at compressed multiples with no near-term commercial catalyst visible in the evidence. The absence of any data makes fundamental assessment speculative, but the idiosyncratic sector divergence tips the balance toward caution.
?Jun 12, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
Moderna (MRNA) has been under sustained fundamental pressure heading into 2026, with declining COVID vaccine revenues, a costly R&D pipeline, and ongoing cash burn that have challenged the bull thesis for several years. With no recent news headlines or SEC filings available in the window, there is no positive catalyst visible to explain a rebound, and the 16.5% drop from the 30-day high may reflect continued deterioration in business fundamentals rather than macro noise. The macro environment (a flattening yield curve, 1.8σ below trend) is also mildly risk-off, which tends to pressure high-beta, pre-profitability biotech names like MRNA.
?Jun 12, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is up ~2.09% today with 330 minutes remaining (essentially a full session ahead), which is ample time for continuation. However, the evidence is mixed: (1) The only directly relevant headline calls MRNA 'slightly overvalued after recent rebound,' which is a mild headwind suggesting the move may be running into resistance or skeptical sell-side framing. (2) The biotech IPO headline (Parabilis +58%) is sector-adjacent and could be contributing to general biotech momentum lifting MRNA, a modest positive. (3) Macro context shows a flattening yield curve (T10Y2Y 2.1σ below trend), which is broadly risk-off for speculative/growth biotech names and may cap upside. (4) No strong catalyst is driving the move — absence of news isn't disqualifying, but combined with the 'overvalued' framing and curve signal, it tilts toward a fade rather than sustained momentum. The 2.09% move is meaningful but sits at the lower bound of the 2-5% 'conviction' range. On balance, there is no strong reason to expect a fade but also no clear continuation pressure; the setup is borderline and resolves at the 0.5 floor per system rules.
✓Jun 12, 9:34 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on MRNA — 5-day return 5.56% with close above 20-day MA ($47.77). IV 62.4%. Sized 1 contract(s) at $3.99 premium.
?Jun 12, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 16.5% from its 30-day high with zero confirmatory signals — no insider buying, no options flow, no SEC filings, and no news headlines to diagnose the cause of the drop. The stock is dipping while the Health Care sector is a strong outperformer (rank 2 of 11, +4.20pts vs SPY over 30 days), which flags idiosyncratic weakness rather than sector-wide pressure — a meaningful concern. Today's broad-market risk-on tone (QQQ +3.30%, SPY +1.70%) provides some potential tailwind, but MRNA's core fundamentals remain challenged: the company has been in post-COVID revenue decline, burning cash on next-generation mRNA pipeline investments, and trades at compressed multiples with no near-term commercial catalyst visible in the evidence. The absence of any data makes fundamental assessment speculative, but the idiosyncratic sector divergence tips the balance toward caution.
▢Jun 11, 8:00 PMjournal
Agent 6 — Options Momentum opened long 30 @ $3.99
▢Jun 11, 8:00 PMjournal
Agent 6 — Options Momentum opened long 70 @ $3.99
?Jun 11, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 16.5% from its 30-day high with zero confirmatory signals — no insider buying, no options flow, no SEC filings, and no news headlines to diagnose the cause of the drop. The stock is dipping while the Health Care sector is a strong outperformer (rank 2 of 11, +4.20pts vs SPY over 30 days), which flags idiosyncratic weakness rather than sector-wide pressure — a meaningful concern. Today's broad-market risk-on tone (QQQ +3.30%, SPY +1.70%) provides some potential tailwind, but MRNA's core fundamentals remain challenged: the company has been in post-COVID revenue decline, burning cash on next-generation mRNA pipeline investments, and trades at compressed multiples with no near-term commercial catalyst visible in the evidence. The absence of any data makes fundamental assessment speculative, but the idiosyncratic sector divergence tips the balance toward caution.
?Jun 11, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
Moderna (MRNA) has been under sustained fundamental pressure heading into 2026, with declining COVID vaccine revenues, a costly R&D pipeline, and ongoing cash burn that have challenged the bull thesis for several years. With no recent news headlines or SEC filings available in the window, there is no positive catalyst visible to explain a rebound, and the 16.5% drop from the 30-day high may reflect continued deterioration in business fundamentals rather than macro noise. The macro environment (a flattening yield curve, 1.8σ below trend) is also mildly risk-off, which tends to pressure high-beta, pre-profitability biotech names like MRNA.
?Jun 11, 12:42 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 19.4% from its 30-day high with a complete absence of confirming signals — no insider buying, no options flow, no recent filings or news to diagnose the cause of the drop. The stock is dipping while its sector (Health Care, XLV) is strongly outperforming the market (+7.41pts vs SPY over 5 days, +4.33pts over 30 days), which is a significant idiosyncratic red flag — this is not a sector-wide move dragging MRNA down but rather company-specific weakness in an otherwise supportive sector. Moderna's post-COVID revenue base remains structurally challenged with no confirmed positive catalyst visible, and the lack of any evidence (filings, insider activity, options call flow) that would suggest informed accumulation limits conviction in a near-term recovery.
?Jun 11, 12:42 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 19.4% from its 30-day high with a complete absence of confirming signals: no insider buying, no unusual options flow, no recent SEC filings, and no news headlines to contextualize the drop. The sector (Health Care / XLV) is actually outperforming SPY meaningfully (+7.41pts over 5 days, rank 2 of 11), which means MRNA's decline is idiosyncratic rather than sector-driven — a concerning divergence that suggests company-specific negative pressure. Moderna's fundamentals remain structurally challenged: post-COVID mRNA revenue has collapsed, the pipeline (flu, RSV, CMV vaccines) faces high clinical and commercial uncertainty, and the company continues burning cash with no near-term profitability catalyst visible in the evidence set.
?Jun 11, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is up ~3% intraday with no attributable headline, suggesting quiet accumulation or technical buying rather than a news-driven spike. With 330 minutes remaining (essentially most of the trading day still ahead), there is ample time for the move to extend. The macro backdrop (T10Y2Y at 1.8σ below trend) is modestly risk-off for banks/defensives but is largely neutral for biotech/pharma like MRNA. No reversal signals are evident from the data provided — the move appears to be holding rather than fading. The absence of a catalyst is a mild concern (no clear narrative to attract additional buyers), and MRNA as a name has historically been volatile with mean-reversion tendencies after sharp moves. Balancing the momentum evidence, neutral macro, no fade signal, and decent time remaining against the lack of a specific catalyst and MRNA's volatile history, a modest continuation probability of 0.54 is appropriate — slight lean toward continuation but not a high-conviction setup.
?Jun 11, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 22.7% from its 30-day high with virtually no supporting evidence to evaluate: no recent news, no SEC filings, no insider activity, and no options flow data. The evidence vacuum makes it impossible to assess whether the drop reflects a temporary overreaction or fundamental deterioration. MRNA has been structurally challenged since its COVID-era peak — declining mRNA vaccine revenue, ongoing pipeline execution risk, and a cash burn profile that raises questions about long-term soundness. While Health Care as a sector is showing relative strength (rank 2/11, outperforming SPY by +4.33pts over 30 days), MRNA's idiosyncratic decline into a sector outperformance window is a concerning signal suggesting company-specific impairment rather than sector-wide headwinds. Broad market is risk-off today (QQQ -2%, SPY -1.58%, VXX +5.68%), adding macro headwinds. The absence of any confirmation signals (no insider buys, no unusual call flow) and no clear catalyst for a large rebound make this setup unattractive for the target asymmetric profile.
?Jun 10, 8:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA has been in a prolonged structural decline as COVID-19 vaccine demand has collapsed and its pipeline (RSV, flu, cancer vaccines) has faced repeated clinical and commercial setbacks. The single available news headline explicitly flags MRNA as a stock to "steer clear of" (negative sentiment), and there are no recent SEC filings to provide reassurance on fundamentals. The macro environment (a flattening yield curve) is not particularly supportive of speculative biotech names with uncertain near-term revenue visibility.
▣Jun 10, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $2.52 (-$66.31)
Stop: premium $2.52 ≤ trailing floor $2.61 (peak $3.48 × 0.75)
✓Jun 10, 11:17 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
PUT on MRNA — 5-day return -5.03% with close below 20-day MA ($47.83). IV 57.4%. Sized 1 contract(s) at $3.18 premium.
?Jun 10, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.2% from its 30-day high with almost no confirming signals: no insider cluster buys, no unusual call flow, no SEC filings, and no near-term catalysts beyond a mildly positive sentiment headline about mRNA advances. Critically, today's broad-market environment is deeply risk-off (QQQ -4.80%, IWM -3.55%, SPY -2.58%), and MRNA is dipping while the Healthcare sector is actually outperforming (rank 2 of 11, +4.87pts vs SPY over 5d), suggesting this is an idiosyncratic decline rather than a sector-wide selloff — a negative signal. Moderna continues to burn cash post-COVID with its revenue and pipeline heavily dependent on mRNA platform commercial success; the lack of a clear fundamental support level makes the asymmetric large-rebound thesis unconvincing.
▢Jun 9, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $3.18
?Jun 9, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The sole analyst note is a maintained Underperform rating from B of A Securities with a price target of $34 — roughly 28% below the current price of $47.54 and well below the 30-day high of $59.48. This suggests the drop is not merely macro noise but reflects persistent fundamental skepticism about MRNA's revenue pipeline beyond COVID vaccines, ongoing cash burn, and lack of near-term catalysts. The macro environment (a flattening yield curve) is not particularly favorable for high-risk, cash-burning biotech names either.
?Jun 9, 12:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.2% from its 30-day high with almost no confirming signals: no insider cluster buys, no unusual call flow, no SEC filings, and no near-term catalysts beyond a mildly positive sentiment headline about mRNA advances. Critically, today's broad-market environment is deeply risk-off (QQQ -4.80%, IWM -3.55%, SPY -2.58%), and MRNA is dipping while the Healthcare sector is actually outperforming (rank 2 of 11, +4.87pts vs SPY over 5d), suggesting this is an idiosyncratic decline rather than a sector-wide selloff — a negative signal. Moderna continues to burn cash post-COVID with its revenue and pipeline heavily dependent on mRNA platform commercial success; the lack of a clear fundamental support level makes the asymmetric large-rebound thesis unconvincing.
?Jun 9, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.2% from its 30-day high with almost no confirming signals: no insider cluster buys, no unusual call flow, no SEC filings, and no near-term catalysts beyond a mildly positive sentiment headline about mRNA advances. Critically, today's broad-market environment is deeply risk-off (QQQ -4.80%, IWM -3.55%, SPY -2.58%), and MRNA is dipping while the Healthcare sector is actually outperforming (rank 2 of 11, +4.87pts vs SPY over 5d), suggesting this is an idiosyncratic decline rather than a sector-wide selloff — a negative signal. Moderna continues to burn cash post-COVID with its revenue and pipeline heavily dependent on mRNA platform commercial success; the lack of a clear fundamental support level makes the asymmetric large-rebound thesis unconvincing.
?Jun 8, 6:26 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The sole analyst note is a maintained Underperform rating from B of A Securities with a price target of $34 — roughly 28% below the current price of $47.54 and well below the 30-day high of $59.48. This suggests the drop is not merely macro noise but reflects persistent fundamental skepticism about MRNA's revenue pipeline beyond COVID vaccines, ongoing cash burn, and lack of near-term catalysts. The macro environment (a flattening yield curve) is not particularly favorable for high-risk, cash-burning biotech names either.
?Jun 8, 6:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The sole analyst note is a maintained Underperform rating from B of A Securities with a price target of $34 — roughly 28% below the current price of $47.54 and well below the 30-day high of $59.48. This suggests the drop is not merely macro noise but reflects persistent fundamental skepticism about MRNA's revenue pipeline beyond COVID vaccines, ongoing cash burn, and lack of near-term catalysts. The macro environment (a flattening yield curve) is not particularly favorable for high-risk, cash-burning biotech names either.
?Jun 8, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.2% from its 30-day high with almost no confirming signals: no insider cluster buys, no unusual call flow, no SEC filings, and no near-term catalysts beyond a mildly positive sentiment headline about mRNA advances. Critically, today's broad-market environment is deeply risk-off (QQQ -4.80%, IWM -3.55%, SPY -2.58%), and MRNA is dipping while the Healthcare sector is actually outperforming (rank 2 of 11, +4.87pts vs SPY over 5d), suggesting this is an idiosyncratic decline rather than a sector-wide selloff — a negative signal. Moderna continues to burn cash post-COVID with its revenue and pipeline heavily dependent on mRNA platform commercial success; the lack of a clear fundamental support level makes the asymmetric large-rebound thesis unconvincing.
?Jun 8, 9:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.2% from its 30-day high with almost no confirming signals: no insider cluster buys, no unusual call flow, no SEC filings, and no near-term catalysts beyond a mildly positive sentiment headline about mRNA advances. Critically, today's broad-market environment is deeply risk-off (QQQ -4.80%, IWM -3.55%, SPY -2.58%), and MRNA is dipping while the Healthcare sector is actually outperforming (rank 2 of 11, +4.87pts vs SPY over 5d), suggesting this is an idiosyncratic decline rather than a sector-wide selloff — a negative signal. Moderna continues to burn cash post-COVID with its revenue and pipeline heavily dependent on mRNA platform commercial success; the lack of a clear fundamental support level makes the asymmetric large-rebound thesis unconvincing.
?Jun 8, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.2% from its 30-day high with almost no confirming signals: no insider cluster buys, no unusual call flow, no SEC filings, and no near-term catalysts beyond a mildly positive sentiment headline about mRNA advances. Critically, today's broad-market environment is deeply risk-off (QQQ -4.80%, IWM -3.55%, SPY -2.58%), and MRNA is dipping while the Healthcare sector is actually outperforming (rank 2 of 11, +4.87pts vs SPY over 5d), suggesting this is an idiosyncratic decline rather than a sector-wide selloff — a negative signal. Moderna continues to burn cash post-COVID with its revenue and pipeline heavily dependent on mRNA platform commercial success; the lack of a clear fundamental support level makes the asymmetric large-rebound thesis unconvincing.
▣Jun 7, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $2.03 (-$205.79)
Stop: premium $2.03 ≤ trailing floor $3.07 (peak $4.09 × 0.75)
?Jun 5, 6:03 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
Today's broad market is under severe pressure (SPY -2.73%, QQQ -4.72%, IWM -3.95%) with VXX +9.06%, creating a deeply risk-off environment that is an unfavorable backdrop for a speculative biotech like MRNA. While there are mildly positive news headlines suggesting Moderna is searching for a post-COVID revenue path, there are no concrete positive catalysts — no insider cluster buys, no unusual call flow, no SEC filings confirming a pipeline catalyst, and no valuation anchor given the company's still-uncertain profitability trajectory. The 21.4% drop from the 30-day high may partly reflect idiosyncratic concern about Moderna's revenue model beyond COVID vaccines, and the sector is underperforming SPY on a 30-day basis (-2.56pts), suggesting the stock is not simply caught in a sector-wide move.
?Jun 5, 3:17 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
Today's broad market is under severe pressure (SPY -2.73%, QQQ -4.72%, IWM -3.95%) with VXX +9.06%, creating a deeply risk-off environment that is an unfavorable backdrop for a speculative biotech like MRNA. While there are mildly positive news headlines suggesting Moderna is searching for a post-COVID revenue path, there are no concrete positive catalysts — no insider cluster buys, no unusual call flow, no SEC filings confirming a pipeline catalyst, and no valuation anchor given the company's still-uncertain profitability trajectory. The 21.4% drop from the 30-day high may partly reflect idiosyncratic concern about Moderna's revenue model beyond COVID vaccines, and the sector is underperforming SPY on a 30-day basis (-2.56pts), suggesting the stock is not simply caught in a sector-wide move.
?Jun 5, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 13.3% from its 30-day high with no clear explanation from available evidence — no SEC filings, no insider activity, and no options flow data to assess sentiment. The news headlines are minimal and uninformative about MRNA specifically. The Health Care sector is ranked 3rd of 11 by 30-day relative strength but is underperforming SPY over 30 days (-2.56pts), suggesting some sector drag, yet MRNA's drop is larger than a typical sector move, implying idiosyncratic pressure. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades), no upcoming earnings catalyst, and no valuation anchor available, the evidence is weak-to-neutral at best. Moderna remains a structurally challenged company post-COVID mRNA cycle, burning cash with limited near-term revenue catalysts.
?Jun 4, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA has been in a prolonged structural decline driven by collapsing COVID vaccine revenues and a still-unprofitable pipeline, making the 13.3% drop difficult to attribute solely to macro noise. The available news is sparse and non-catalytic — one headline questions sector outperformance without offering positive signals, and there are no recent SEC filings to confirm balance sheet stability or a pipeline catalyst. The macro context (a flattening yield curve) is mildly negative for risk assets but is not the primary driver of concern here; MRNA's fundamental trajectory (cash burn, shrinking addressable market) remains the dominant headwind.
?Jun 4, 6:03 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 13.3% from its 30-day high with no clear explanation from available evidence — no SEC filings, no insider activity, and no options flow data to assess sentiment. The news headlines are minimal and uninformative about MRNA specifically. The Health Care sector is ranked 3rd of 11 by 30-day relative strength but is underperforming SPY over 30 days (-2.56pts), suggesting some sector drag, yet MRNA's drop is larger than a typical sector move, implying idiosyncratic pressure. With no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades), no upcoming earnings catalyst, and no valuation anchor available, the evidence is weak-to-neutral at best. Moderna remains a structurally challenged company post-COVID mRNA cycle, burning cash with limited near-term revenue catalysts.
✓Jun 4, 6:03 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on MRNA — 5-day return 8.45% with close above 20-day MA ($48.82). IV 64.7%. Sized 1 contract(s) at $4.09 premium.
▢Jun 3, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $4.09
▣Jun 2, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 200 @ $2.14 (-$247.70)
Stop: premium $2.14 ≤ trailing floor $2.79 (peak $3.71 × 0.75)
▢May 31, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 28 @ $48.89
▢May 31, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 29 @ $48.89
▢May 21, 8:00 PMjournal
Agent 6 — Options Momentum opened long 200 @ $3.38
▣May 20, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 200 @ $3.21 (-$22.63)
Stop: premium $3.21 ≤ trailing floor $3.39 (peak $4.53 × 0.75)
▢May 18, 8:00 PMjournal
Agent 6 — Options Momentum opened long 200 @ $3.32

← Back to dashboard